Early Intervention With Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared With Population Normative Data AND Early Intervention With Epoetin Alfa During Platinum

Early Intervention With Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared With Population Normative Data AND Early Intervention With Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of the Results of a Multicenter, Randomized, Controlled Trial Based on Initial Hemoglobin Level Jorine H. Savonije, Cees J. van Groeningen, Lars W. Wormhoudt, Guiseppe Giaccone Oncologist 2006; 11: 197-216 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in symptom management and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the implications of untreated anemia and the benefits of anemia prevention/early correction in patients with cancer receiving chemotherapy. Relative to population norms, describe the quality-of-life results of a prospective, randomized study in which cancer patients with baseline Hb levels ?12.1 g/dl received epoetin alfa or best supportive care. Discuss the effect of initial Hb level on the results of a prospective, randomized study in which cancer patients with baseline Hb levels ?12.1 g/dl received epoetin alfa or best supportive care during platinum-based chemotherapy. Explain that the positive effects of early intervention with epoetin alfa on the transfusion rate, hematopoietic response, and quality of life in patients with chemotherapy-related anemia occur regardless of baseline Hb level, and that treating patients to an Hb value of 12.0 g/dl is clinically appropriate to optimize quality-of-life outcomes. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Feb. 13, 2006 Most Recent Review: May 8, 2007* Most Recent Update: May 8, 2007 Date Credit Expires: Feb. 13, 2008 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.